Atorvastatin pills

61433USD

Description

Features

Reviews

Instructions for Atorvastatin pills

English product name
Atorvastatin

Release form
tab. film sheath, 10 mg: 10, 20, 30, 40, 50, 60, 90, 100, 120, 270 or 300 pcs.
tab. film sheath, 20 mg: 10, 20, 30, 40, 50, 60, 90, 100, 120, 270 or 300 pcs.
tab. film sheath, 40 mg: 10, 20, 30, 40, 50, 60, 90, 100, 120, 270 or 300 pcs.
tab. film sheath, 80 mg: 10, 20, 30, 40, 50, 60, 90, 100, 120, 270 or 300 pcs.

Description
The tablets are covered with a film shell of white or almost white color, round double-convex, with a white kernel on the fracture.

1 tab.
atorvastatin calcium trihydrate 10.84 mg
which corresponds to the content of atorvastatin 10 mg
Auxiliary substances: lactose monohydrate - 43.71 mg, cellulose microcrystalline - 15 mg, sodium lauryl sulfate - 0.5 mg, povidon K-25 - 2.5 mg, calcium carbonate - 17.5 mg, sodium carboxymethylstarch - 4 mg, magnesium stearate - 0.95 mg.

The composition of the film sheath: hypromellose - 1.71 mg, macrogol-4000 - 0.45 mg, titanium dioxide - 0.84 mg.

ATC codes
C10AA05 Atorvastatin

Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug

Active substance
atorvastatin

Pharmacotherapy group Atorvastatin

Hypolipidemic agent - reductase inhibitor GMG-CoA

Pharmacological effect Atorvastatin

Hypolipidemic agent from the group of statins. By the principle of competitive antagonism, the statin molecule binds to the part of the coenzyme A receptor where GMG-CoA reductase is attached. Another part of the statin molecule inhibits the process of converting hydroxymethylglutarate into mevalonate, an intermediate product in the synthesis of the cholesterol molecule. Inhibition of HMG-CoA reductase activity results in a series of sequential reactions that reduce intracellular cholesterol and compensatory enhancement of LDL receptor activity and, correspondingly, acceleration of LDL cholesterol catabolism (Xc).

Testimony Atorvastatin

Primary hypercholesterolaemia (heterozygous familial and nonfamilial hypercholesterolaemia
(type IIa of Fredrikson's classification); combination (mixed) hyperlipidemia
(types IIa and IIb of Fredrikson's classification);
dysbetalipoproteinemia (type III of Fredrikson's classification)
(as a supplement to the diet); family endogenous hypertriglyceridemia (type IV of Fredrikson's classification),
diete-resistant;
homozygous familial hypercholesterinemia with insufficient efficacy Dieting and other non-pharmacological treatments.
Primary prevention of cardiovascular complications in patients without clinical signs of IBS,
but with several risk factors of its development - age over 55 years,
nicotine dependence,
arterial hypertension,
diabetes mellitus,
low concentrations of Hs-HDL in blood plasma,
genetic predisposition,
including on the background of dylipidemia.
Secondary prevention of cardiovascular complications in patients with IBS in order to reduce total mortality,
myocardial infarction,
stroke,
repeated angina hospitalization and the need for revascularization.

Method of use, course and dosage Atorvastatin

The treatment is carried out against a standard diet for patients with hypercholesterolemia. The dose is set individually, depending on the initial cholesterol level. Taken inside. The initial dose is usually ten mg once a day. The effect lasts two weeks and the maximum effect lasts four weeks. If necessary, the dose can be gradually increased at intervals of four weeks or more. The maximum daily dose is 80 mg.